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Cisplatin plus paclitaxel, and subsequently carboplatin plus pacli-
taxel, have become the most widely accepted first-line chemo-
therapy regimens for advanced epithelial ovarian cancer (1–4). 
Despite the improvements in outcome afforded by this treatment, 
the great majority of women with ovarian cancer will relapse and 
eventually die of their disease. One approach to try to improve this 
treatment is to add a third active agent to the carboplatin–
paclitaxel combination. The camptothecin analog, topotecan, has 
shown activity in the treatment of recurrent ovarian cancer, 
including platinum-resistant disease (5–9). However, combining 
topotecan with carboplatin and paclitaxel as a triplet therapy is 
problematic due to myelosuppression (10). To address this prob-
lem, the NCIC Clinical Trials Group (NCIC CTG) tested an 
approach of sequential doublets of cisplatin plus topotecan fol-
lowed by carboplatin—paclitaxel as a means of integrating this 
third agent into the standard regimen. The activity seen in the 
phase II study of this combination (11) was sufficient to warrant 
phase III investigation. This report outlines the results of a ran-
domized phase III study that compares standard carboplatin plus 
paclitaxel to the triple drug combination regimen including topo-
tecan. The trial was conducted by the NCIC CTG, the European 
Organization for Research and Treatment of Cancer–Gynecologic 
Cancer Group (EORTC-GCG) and the Grupo de Investigación 
de Cáncer de Ovario (GEICO) cooperative groups under the 
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 Background  Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination com-
pared with standard frontline therapy.
  Methods  Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative 
Oncology  Group  Performance  Status  of  1  or  less,  were  stratified  by  type  of  primary  surgery  and  residual 
disease,  treatment  center,  and age;  then  randomly assigned  to one of  the  two 21-day  intravenous  regimens. 
Patients in arm 1 (n = 409) were administered four cycles of cisplatin 50 mg/m2 on day 1 and topotecan 0.75 mg/m2 
on days 1–5, then four cycles of paclitaxel 175 mg/m2 over 3 hours on day 1 followed by carboplatin (area under 
the curve = 5) on day 1. Patients in arm 2 (n = 410) were given paclitaxel plus carboplatin as in arm 1 for eight 
cycles. We  compared  progression-free  survival  (PFS),  overall  survival,  and  cancer  antigen-125  normalization 
rates  in  the  two  treatment arms. A stratified  log-rank  test was used  to assess  the primary endpoint, PFS. All 
statistical tests were two-sided.
  Results  A total of 819 patients were randomly assigned. At baseline, the median age of the patients was 57 years (range = 
28–78); 81% had received debulking surgery, and of these, 55% had less than 1 cm residual disease; 66% of 
patients were stage III and 388 (47.4%) patients had measurable disease. After a median follow-up of 43 months, 
650 patients had disease progression or died without documented progression and 406 had died. Patients  in 
arm 1 had more hematological toxicity and hospitalizations than patients in arm 2; PFS was 14.6 months in arm 
1 vs 16.2 months in arm 2 (hazard ratio = 1.10, 95% confidence interval = 0.94 to 1.28, P = .25). Among patients 
with elevated baseline cancer antigen-125, fewer in arm 1 than in arm 2 had levels return to normal by 3 months 
after random assignment (51.6% vs 63.3%, P = .007)
 Conclusions  Topotecan and cisplatin, followed by carboplatin and paclitaxel, were more toxic than carboplatin and paclitaxel 
alone,  but without  improved  efficacy.  Carboplatin  plus  paclitaxel  remains  the  standard  of  care  for  advanced 
epithelial ovarian cancer.
    J Natl Cancer Inst 2010;102:1547–1556
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auspices of the Gynecologic Cancer Intergroup in women with 
newly diagnosed advanced epithelial ovarian or fallopian tube or 
primary peritoneal cancers.
Patients and Methods
Eligibility
Eligible women had newly diagnosed, chemotherapy-naive, epi-
thelial ovarian, fallopian tube, or primary peritoneal cancer and 
had completed all planned primary surgery. Other entry criteria 
included: International Federation of Gynecology and Obstetrics 
(FIGO) stage IIB to IV disease; Eastern Cooperative Oncology 
Group (ECOG) performance status 0 or 1; age 18–75 years; ade-
quate hematological reserve (granulocytes ≥ 2 × 109/L, platelets ≥ 
150 × 109/L) and renal function (creatinine ≤ upper normal limit); 
and written informed consent. Patients were excluded if they had 
any of the following conditions: borderline ovarian tumors, prior 
nonsurgical therapy for ovarian cancer, prior history of another 
malignancy (except nonmelanoma skin cancer, in situ cervical can-
cer, or a solid tumor treated with curative intent with no evidence 
of disease for five or more years), clinically apparent myocardial 
infarction within the proceeding 6 months, second- or third-
degree heart block unless a pacemaker had been implanted, contra-
indication to high volume saline diuresis, preexisting hearing loss, 
or neuropathy greater than grade 1. The diagnosis of cancer was 
expected to be based on histological findings; however, cytological 
diagnosis was also allowed for women who did not have a tissue 
diagnosis provided that the patient met the following criteria: a 
pelvic mass with an abdominal metastasis 2 cm in diameter or 
larger (unless proven stage IV disease), a normal mammogram 
within the preceding 6 weeks, and a cancer antigen-125 (CA125) 
to carcinoembryonic antigen ratio of 25 or greater. If the CA125 
to carcinoembryonic antigen ratio was less than 25, patients were 
eligible providing that colonoscopy (or barium enema) and gas-
troscopy (or barium meal) were negative. Participating institutions 
had to have obtained required research ethics committee approval 
to enroll patients on this study. The clinical trial registration 
number is NCT00028743 (www.clinicaltrials.gov).
Treatment
Patients in arm 1, the experimental arm, were given the following 
treatment: cisplatin 50 mg/m2 intravenously over 60 minutes on 
day 1 followed by topotecan 0.75 mg/m2 intravenously for 5 days 
over 30 minutes on days 1 through 5 for four cycles at 3-week 
intervals. This was then followed by four cycles of intravenous 
carboplatin (area under the curve = 5) over 30 minutes (or per in-
stitutional standard) and paclitaxel 175 mg/m2 over 3 hours at 
3-week intervals. The carboplatin dose was calculated using either 
the measured glomerular filtration rate by nuclear renogram or a 
calculated glomerular filtration rate using the Cockcroft formula.
Patients in arm 2, the standard treatment arm, were given car-
boplatin (area under the curve = 5) as above plus paclitaxel 175 mg/
m2 over 3 hours every 3 weeks for eight cycles. Interval debulking 
surgery (for those not optimally debulked at the time of study 
entry) was allowed in both arms after three or four cycles of 
therapy.
All drugs were administered in solution as per their product 
monographs with hydration and premedication according to local 
institutional standards. (The trial protocol did not specify such 
standards.)
The protocol’s dose reduction criteria were the same for both 
arms. If, in arm 1, granulocytes were less than 0.5 × 109/L for more 
than 7 days, or platelets less than 25 × 109/L, or there had been 
febrile neutropenia, or an infection (≥ grade 3) with neutropenia, 
then topotecan was to be decreased by 25% in the next cycle, with 
no change in cisplatin dosing. For patients who developed the 
same findings while on carboplatin plus paclitaxel (cycles 4–8 for 
arm 1 or cycles 1–8 for arm 2), paclitaxel was to decrease by 25 mg/m2 
and carboplatin was to decrease by 1 area under the curve. 
Treatment was to be delayed until recovery of blood counts if the 
granulocytes were less than 1.5 × 109/L or platelets under 100 × 
109/L upon the treatment day. Other dose modifications were 
made based on adverse effects graded using the Common Toxicity 
Criteria version 2.0 as follows: for grade 3 arthralgia or myalgia, 
paclitaxel was reduced by 25 mg/m2, and for grade 4, paclitaxel was 
stopped; for grade 4 (life threatening) anaphylaxis, the protocol 
therapy was discontinued; for grade 2 neurotoxicity, paclitaxel was 
reduced by 25 mg/m2 and for grade 3 neurotoxicity, the protocol 
therapy was discontinued; for grade 2 or worse mucositis, pacli-
taxel was reduced by 25 mg/m2; for renal toxicity (after rehydra-
tion) with creatinine levels at 1–1.5 × upper limit of normal, 
cisplatin was reduced by 25%, if creatinine levels were greater than 
1.5 × upper limit of normal, the protocol therapy was discontinued.
On Treatment Investigations
On day 1 of each cycle, a physical examination was performed and 
measurements of complete blood count, serum creatinine, aspar-
tate transaminase (or alanine transaminase), and serum CA125 
CONTEXT AND CAVEATS
Prior knowledge
Although  as  a  single  agent,  topotecan  has  shown  some  activity 
against ovarian cancer,  it was not known whether adding topote-
can to a standard combination treatment for ovarian cancer would 
improve patient outcomes.
Study design
Here,  819 women with  stage  IIB  or  greater  ovarian  cancer were 
randomly assigned to carboplatin–paclitaxel or to cisplatin–topotecan 
followed  by  carboplatin–paclitaxel.  Progression-free  survival  and 
overall  survival were measured,  in addition  to adverse effects, 
quality of life, and CA125 normalization.
Contribution
Patients  in  the  treatment  arm  that  included  topotecan  had more 
adverse effects and no improvement in progression-free survival.
Implications
Carboplatin plus paclitaxel remains the best treatment for epithe-
lial ovarian cancer stage IIB or greater.
Limitations
It  is  too  early  to  determine  the  effects  of  the  new  treatment  on 
overall survival.
From the Editors
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were obtained. On day 15 of each cycle, a complete blood count 
was performed. More frequent investigations were conducted if 
they were indicated medically.
Imaging of the abdomen–pelvis (either by computed tomogra-
phy scan or magnetic resonance imaging) was required postopera-
tively before cycle 1 treatment to obtain baseline measures, except 
when no debulking had been undertaken (biopsy ≤ 1 cm or fine 
needle aspiration only, in which case the preoperative scan was 
used) or when optimal debulking had been achieved (largest re-
sidual lesion <1 cm, in which case no scans were required). Further 
imaging in all patients, using the same technique throughout, was 
to be carried out after cycle 4 (or cycle 3 if interval debulking was 
planned), and then again after cycle 8 or earlier if progression was 
suspected. Quality of life (QoL) was assessed using the EORTC 
quality-of-life questionnaires (QLQs) C30 and OV28 module at 
baseline and then on day 1 at cycles 3, 5 and 7, and at the end of 
the last cycle.
Post-Treatment Follow-up
All patients were to be observed every 3 months for the first 3 years 
after the end of treatment, then every 6 months for 2 years, and 
then annually. History, physical examination, and measurement of 
CA125 levels were required at each visit. Imaging was not rou-
tinely mandated at these time points but instead was performed at 
the physician’s discretion based on CA125 levels and physical ex-
amination or symptomatic findings. QoL questionnaires [EORTC 
QLQ C30 (12) and OV28 module (13)] were to be completed 3 
and 6 months after the end of protocol therapy in all patients. The 
QLQ C30 contains nine multi-item scales: five functional scales 
(physical, role, cognitive, emotional, and social), three symptom 
scales (fatigue, pain, and nausea and vomiting), and a global health 
and QoL scale. The OV28 module assesses symptoms that may be 
specific to ovarian cancer or its treatment including abdominal 
symptoms, peripheral neuropathy, hormonal symptoms, attitude 
to disease and treatment, and sexual functioning.
Endpoints
The primary endpoint was progression-free survival (PFS), which 
was defined as the time from random treatment allocation until the 
time when the first observation of disease progression or death 
without progression was documented. The Gynecologic Cancer 
Intergroup definition of progression was used. Both objective pro-
gression [using Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria (14)] and CA125 progression were included 
(15). Briefly, objective progression was documented on the basis of 
either a 20% increase in the sum of diameters over the nadir on 
study or the appearance of new disease. CA125 progression 
required an increase to at least twice the upper limit of normal (or 
of the nadir value if normalization was never achieved) confirmed 
at least 1 week later. If both events occurred in the same patient, 
the earlier of the two dates was considered the date of progression 
for the analysis. CA125 values obtained within 4 weeks of surgery 
or other invasive abdominal procedures (eg, paracentesis) were not 
to be counted because it is known that these maneuvers could 
produce rises in CA125.
Secondary endpoints included overall survival (from date of 
random assignment to death from any cause), toxic effects, QoL 
assessed by EORTC QLQ C30 (12) and OV28 module (13), 
objective response rate [in patients with measurable disease as 
assessed by RECIST criteria), and CA125 normalization rates 3 
months after random assignment (16,17)].
Statistical Considerations
Treatment Allocation. Patients were stratified by treatment cen-
ter, age (≤65 or >65 years), and extent of surgery before treatment 
allocation (no debulking, no macroscopic residual, macroscopic 
residual <1 cm, or macroscopic residual ≥1 cm). A computerized 
minimization procedure, which uses simple randomization only 
when there are ties between treatment groups, was used to allocate 
patients randomly 1:1 to one of the two treatments (18).
Sample Size Calculation. Previous trials that investigated 
platinum–paclitaxel combination therapy in this setting observed a 
PFS of approximately 16 months. To have an 80% power to detect 
a 25% improvement in PFS (ie, from a median of 16 months to 20 
months; hazard ratio [HR] = 0.8) using a two-sided 5% alpha, one 
would need to observe, at the time of the final analysis, a total of 
631 progression events (defined as above). Random assignment of 
800 patients (400 in each group) over 2 years would be expected to 
lead to the required number of progression events after a further 
29 months of follow-up.
Statistical Analysis. PFS and overall survival were compared 
between the two treatment arms by a stratified log-rank test, and 
response rates and CA125 normalization rates were compared at 3 
months by the Cochran–Mantel–Haenzel test, all adjusting for the 
three stratification factors (treatment centers within each group 
combined, age, extent of pre-randomization surgery) at the time of 
random assignment. All patients randomly assigned were included 
in the analyses of these endpoints based on intention-to-treat prin-
ciple. A Cox proportional hazard model, which included, besides 
treatment and the three stratification factors listed above, stage of 
disease (II vs III or IV), grade (well or moderate vs poor, undifferen-
tiated or unknown), histology (serous adenocarcinoma vs others), 
performance status (0 vs 1) as covariates, was used to assess the treat-
ment effect after adjusting for the additional potential predictors and 
to identify factors predictive of PFS. The assumption of proportion-
ality in Cox model was assessed by Schoenfeld residuals.
All patients who received at least one dose of protocol treat-
ment were included in the safety and treatment exposure analyses. 
Fisher exact test was used to compare incidence of adverse events 
between treatment arms. Changes of QoL scores from baseline in 
each QoL scale at each assessment point were compared between 
two treatment arms by the Wilcoxon rank sum test. All patients 
who had both QoL assessment at baseline and the given assess-
ment point were included in the analysis. All comparisons between 
treatment arms were carried out using two-sided tests at an alpha 
level of 5%.
Results
Patient Enrollment and Characteristics
This study evaluated a novel topotecan-based triple drug combi-
nation regimen compared with standard paclitaxel and carboplatin 
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in women with advanced ovarian cancer. Between August 31, 
2001, and June 29, 2005, a total of 819 patients (471 from the 
NCIC CTG, 219 from the EORTC-GCG, and 129 from 
GEICO) were randomly assigned to four cycles of cisplatin and 
topotecan followed by four cycles of paclitaxel and carboplatin or 
to eight cycles of paclitaxel and carboplatin. All were included in 
the intention-to-treat efficacy analysis (Figure 1). After the 
number of required progression events had been achieved, the 
database was locked for final analysis on March 5, 2008. At base-
line, median age of the patients was 57 years (range = 28–78); 81% 
had received debulking surgery, and of these 55% had less than 1 
cm residual disease; 66% of patients were stage III and 388 
(47.4%) patients had measurable disease. The two treatment arms 
were balanced with respect to prior surgery; residual disease; age; 
grade; histology; baseline CA125 levels presence of measurable 
disease; and global QoL, fatigue, and peripheral neuropathy 
scores (Table 1). There was one patient who was 78-years-old, 
and primary conclusion remained the same when this patient was 
excluded from analysis.
Treatment Delivery
Four patients (three in arm 1 and one in arm 2) never received any 
treatment or withdrew their consent before the first dose of the 
treatment and were excluded from analyses on treatment exposures 
and safety. The majority of patients in both treatment arms 
completed eight cycles of therapy (78% patients in arm 1 and 81% 
in arm 2). However, 85% of arm 1 patients had at least one cycle 
delayed as compared with 50% of patients in arm 2. Most delays 
for arm 1 patients (77%) were in the first four cycles of topotecan–
cisplatin and were related to myelosuppression. Dose reductions 
were similarly more common in arm 1 than in arm 2: 43% vs 18% 
(Table 2).
Adverse Effects
Common adverse effects seen in the study included gastrointesti-
nal symptoms, myelosuppression, neurological toxicity, and my-
algia (Table 3). Patients in arm 1 had substantially more 
myelotoxicity than patients in arm 2, with an 85% rate of grade 4 
granulocytopenia in arm 1 vs 58% in arm 2 with almost all of this 
differential rate seen during the topotecan portion of the regimen. 
The rates of febrile neutropenia or infection with grade 3 or 4 
neutropenia were 22% among arm 1 patients and 6% among arm 
2 patients, and granulocyte colony-stimulating factor use was more 
common in arm 1 as noted below. Four deaths on study were at-
tributed to sepsis, two in each arm (0.5% of patients). Other toxic 
effects that were more frequent in arm 1 included thromboembolic 
events, nausea, and vomiting. Arm 2 patients had substantially 
more neurosensory effects and allergic reactions. Hospitalization 
during treatment was more common for arm 1 than arm 2 patients 
(11.3% cycles vs 7.1% cycles, respectively).
Figure 1. Consolidated Standards of Reporting 
Trials diagram.
819 patients randomly 
assigned
409 in analyses for 
efficacy
410 in analyses for 
efficacy
8 ineligible7 ineligible
3 never received 
treatment
1 never received 
treatment
406 in safety analyses 409 in safety analyses
409 to arm 1 410 to arm 2
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Table 1. Baseline patient characteristics*
Characteristic
Arm 1  
(experimental  
treatment)
Arm 2  
(standard  
treatment)
Total randomly assigned and  
    included in the analysis,  
    No. (%)
409 (100) 410 (100)
Eligible, No. (%) 402 (98.3) 402 (98)
Ineligible, No. (%) 7 (1.7) 8 (2)
  Wrong ovarian pathology 2 3
  Nonovarian cancer 1 1
  Baseline grade III hearing loss 1 2
  Relapsed disease 1 0
  Wrong stage 1 0
  Concurrent serious illness 1 0
  Prior malignancy 0 2
Age , median (range), y 57 (28–78) 57 (33–75)
ECOG performance status,  
    No. (%)
 
  0 138 (34) 125 (31)
  1 271 (66) 285 (70)
Cancer site, No. (%)  
  Ovary 368 (90) 362 (88)
  Fallopian tube 6 (2) 15 (4)
  Peritoneal 33 (8) 30 (7)
  Other 2 3
Residual disease, No. (%)  
  None/micro 90 (22) 92 (22)
  Macro < 1 cm 102 (25) 83 (20)
  Macro ≥ 1 cm 135 (33) 149 (36)
  No debulking 76 (19) 81 (20)
  Unknown 6 (1) 5 (1)
FIGO stage, No. (%)  
  IIA 1 (0.2) 0 (0.0)
  IIB 14 (3.4) 7 (1.7)
  IIC 22 (5.4) 26 (6.3)
  IIIA 14 (3.4) 12 (2.9)
  IIIB 32 (7.8) 43 (10.5)
  IIIC 229 (56.0) 210 (51.2)
  IV 97 (23.7) 112 (27.3)
Measurable disease,  
    No. (%)
195 (48) 193 (47)
Histology, No. (%)  
  Serous 265 (65) 280 (68)
  Clear 24 (6) 20 (5)
  Mixed 31 (8) 28 (7)
  Endometrioid 28 (7) 22 (5)
  Mucinous 9 (2) 10 (2)
  Unspecified 39 (10) 36 (9)
  Other 13 (3) 14 (3)
CA125 at baseline, median  
    (range), U/mL
212 (4–234) 217 (4–424)
Quality of life  
  Global  
    No. of patients 349 344
    Mean score (SD) 53.0 (24.9) 51.9 (23.9)
  Fatigue  
    No. of patients 353 350
    Mean score (SD) 47.6 (26.0) 48.0 (25.2)
  Peripheral neuropathy  
    No. of patients 347 336
    Mean score (SD) 9.7 (14.0) 9.5 (12.7)
*  ECOG = Eastern Cooperative Oncology Group; FIGO = International 
Federation of Gynecology and Obstetrics.
Supportive Care
In keeping with the observations of greater hematological toxicity 
in arm 1, more patients received hematopoietic growth factors 
support in that arm. Of the treated patients, 105 (25.8%) on arm 1 
received erythropoietin, vs 55 (13.4%) on arm 2. A total of 141 
patients (34.7%) in arm 1 received a granulocyte colony-stimulating 
factor preparation while on therapy vs 56 (13.7%) in arm 2.
Interval Debulking
The study protocol allowed interval debulking to be undertaken in 
those patients who were not optimally debulked at baseline. A total 
of 126 patients underwent interval debulking, almost all after cycle 
3 or 4. A somewhat greater proportion of arm 2 patients had inter-
val debulking (71 patients; 17.4%) compared with arm 1 patients 
(55 patients; 13.5%).
Quality of Life
QoL questionnaires were completed at baseline by 90.5% and 
87.4% of patients in arms 1 and 2, respectively. At the final 
6-month follow-up assessment, compliance rates dropped to 
55.9% and 59.4% patients, respectively, with no substantial differ-
ence between treatment arms. A full report of QoL analysis will 
be presented in a separate paper, so only key findings are high-
lighted here: Over the course of the study, the global QoL score 
increased both statistically (all P < .001) and clinically (defined as 
a 10-point increase from baseline) from baseline with no statisti-
cally significant differences between treatment arms at any assess-
ment time point after baseline (Figure 2,A). Fatigue similarly 
improved (statistically and clinically as a 10-point decrease from 
baseline) from baseline with no statistically significant difference 
between the arms (Figure 2,B). Corroborating the toxicity data, 
there were statistically significantly more instances of self-
reported peripheral neuropathy at cycles 3 and 5 in arm 2 (P < 
.001). By the 6-month follow-up, these scores had substantially 
decreased from their peaks at the end of treatment in both groups 
with no between-group differences. However, peripheral neurop-
athy in both arms remained clinically significantly higher than at 
baseline (Figure 2,C).
Efficacy
Objective Response. Best response to treatment was assessed in 
those patients who had measurable disease at baseline: 196 in arm 
1 and 193 in arm 2. Overall response rates were statistically signif-
icantly lower in arm 1 (133 of 196; 67.9%) than in arm 2 (149 of 
193; 77.2%; P = .04). Complete responses were seen in 61 (31.1%) 
arm 1 and 72 (37.3%) arm 2 patients. The difference in overall 
response rates became borderline significant (P = .08) in a logistic 
regression model that adjusted for both stratification factors and 
other potential prognostic factors (stage, grade, histology, and 
performance status).
CA125 Normalization. When the entire randomly assigned pop-
ulation was examined, the proportion of patients with normalized 
CA125 at or before 3 months after randomization were statistically 
significantly greater in arm 2 than arm 1 patients (66.3% vs 57.5%; 
P = .006). Restricting this analysis to the 602 patients with elevated 
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Table 2. Dose delivery: percentage of planned dose*
Arm 1 Arm 2
Cisplatin Topotecan Paclitaxel Carboplatin Paclitaxel Carboplatin
Total dose planned 200 mg/m2 15 mg/m2 700 mg/m2 AUC 20 1400 mg/m2 AUC 40
Total dose received, %  
    patients receiving this  
    dose range
         
  ≥90% 79.6 56.9 77.7 79.9 76.0 73.6
  ≥80, <90 3.2 18.5 9.2 4.9 6.4 8.4
  ≥60, <80 8.1 14.3 6.0 8.4 8.1 7.4
  <60 9.1 10.3 7.1 6.8 9.5 10.6
*  AUC = area under the curve.
Table 3. Adverse effects: worst by patient
Adverse events
Arm 1 Arm 2
P*Patients, No. (%) Patients, No. (%)
Total† 406 (100) 409 (100)
Nonhematological (all grades)    
  Allergic reaction 97 (24) 145 (35) <.001
  Hair loss 358 (88) 368 (90) .43
  Fatigue 355 (87) 339 (83) .08
  Anorexia 177 (44) 164 (40) .32
  Thromboembolic events 28 (7) 8 (2) <.001
  Nausea 341 (84) 314 (77) .01
  Vomiting 233 (57) 167 (41) <.001
  Diarrhea 150 (37) 145 (35) .66
  Stomatitis 166 (41) 153 (37) .31
  Febrile neutropenia or infection with grade 3/4 neutropenia 88 (22) 25 (6) <.001
  Neurosensory 301 (74) 344 (84) < .001
  Myalgia 249 (61) 260 (64) .51
  Abdominal pain 200 (49) 192 (47) .43
Hematological    
  Granulocytes grade 4 344 (85) 234 (58) <.001
  Platelets grade 3 or 4 185 (46) 37 (9) <.001
*  P values (two-sided) were calculated using the Fisher exact test. 
†  Four patients (three in arm 1 and one in arm 2) never received any treatment or withdrew their consent before the first dose of the treatment and were excluded 
from analyses on treatment exposures and safety.
baseline CA125 values who had at least one follow-up CA125 de-
termination (308 in arm 1 and 294 in arm 2) gave a similar result: 
normalization rates were 186 of 294 (63.3%) in arm 2 and 159 of 
308 (51.6%) in arm 1 (P = .007).
The proportion of patients with CA125 normalization at the 
end of the protocol treatment and at any time during the follow-up 
were 81.2% and 83.2%, respectively, for arm 2 and 74.3% and 
78.2%, respectively, for arm 1. A landmark analysis (excluding 
those women who had either progression of ovarian cancer before 
3 months on study, or who were on study for less than 3 months, 
or who had no CA125 assessment before 3 months on study) 
showed that CA125 normalization by 3 months after random as-
signment was statistically significantly associated with PFS (HR for 
those with vs without CA125 normalization was 0.29, 95% confi-
dence interval [CI] = 0.25 to 0.34; P < .001). CA125 normalization 
by 6 and 9 months after random assignment was similarly associ-
ated with PFS [HR for those with vs without CA125 normalization 
by 6 months after random assignment = 0.25 (95% CI = 0.20 to 
0.31) and HR for those with vs without CA125 normalization by 9 
months after random assignment = 0.28 (95% CI = 0.21 to 0.39)].
Progression-free Survival. At the time of analysis (March 5, 
2008 database), after a median follow-up of 43 months, 650 pro-
gression events had been documented. Kaplan–Meier curves il-
lustrate the PFS outcomes in the study arms (Figure 3). There 
was no statistically significant difference in the outcomes: the 
median PFS was 14.6 months and 16.2 months in arms 1 and 2, 
respectively (HR = 1.10, 95% CI = 0.94 to 1.28; P =.25). In a 
multivariable analysis that adjusted for both stratification factors 
and other prespecified covariates including stage (II vs III or IV), 
grade (well or moderate vs poor and undifferentiated or 
unknown), histology (serous vs others), and ECOG performance 
status (0 vs 1) as covariates, the treatment difference was still not 
statistically significant (adjusted HR = 1.11, 95% CI = 0.95 to 
1.30, P = .20). Debulking, FIGO stage II, and performance status 
0 were independent factors that were associated with better sur-
vival (Table 4). PFS was statistically significantly different for 
arm 2 when subdivided by minimal (<1 cm) or bulk residual (≥1 cm) 
(HR = 1.51, 95% CI = 1.11 to 2.09, P = .008). For arm 1, the 
difference approached statistical significance (HR = 1.21, 95% 
CI = 0.97 to 1.76, P = .09).
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Figure 2. Change in quality-of-life measures from baseline over time 
by  treatment  arms.  Patients  completed  questionnaires  (European 
Organization  for  Research  and  Treatment  of  Cancer–quality-of-life 
questionnaires C30 and OV28 module) at baseline, day 1 on cycles 3, 5, 
and 7, at the end of the last cycle, and then 3 and 6 months after the end 
of protocol therapy. The mean change scores from baseline is plotted. 
In each graph, arm 1 is indicated by a solid line and arm 2 is indicated 
by  a  dashed line.  Panels  are  as  follows: A)  global  quality  of  life, B) 
fatigue, and C) peripheral neuropathy. In panel A, positive change indi-
cates  improvement, but  in panels B and C, negative change indicates 
improvement.  N  =  number  of  patients  with  quality-of-life  measure-
ments; M = mean change score, with 95% confidence interval in paren-
theses;  fu  =  follow-up.  The  asterisks  in  panel  C  indicate  a  statistical 
significant  difference  between  the  treatment  arms  (P  <  .001,  by  a 
two-sided Wilcoxon rank sum test).
A 1 A 2
Month N S 95% CI N S       95% CI
12 248 60.6  (55.9 to 65.4) 283 69.5  (65.1 to 74.0)
24 133 32.5  (28.0 to 37.1) 132 32.6  (28.1 to 37.2)
36 65 21.5  (17.4 to 25.6) 74 23.9  (19.6 to 28.1)
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Figure 3. Kaplan–Meier curves for progression-free survival. An event is 
defined as disease progression or death without progression.  In each 
graph, arm 1  is  indicated by a solid line  and arm 2  is  indicated by a 
dashed line. No significant differences were found between the treat-
ment arms. N = number at  risk; S = survival percent, with 95% confi-
dence interval in parentheses.
Overall Survival. A total of 406 deaths had been reported at the 
time of data cutoff with a median overall survival of 42.3 and 42.1 
months in arms 1 and 2, respectively (Figure 4). A more definitive 
analysis of overall survival will be performed when 631 deaths are 
observed so as to have an 80% power to detect the same hazard 
ratio for PFS (0.8, which is corresponding to an increase of 8.75 
months in median survival from 35 months to 43.75 months) at a 
two-sided .05 level.
Discussion
In this multinational phase III study for women with advanced 
(stage IIB or higher) epithelial ovarian, peritoneal, or fallopian 
tube cancers, first-line therapy with sequential doublets of cis-
platin and topotecan followed by carboplatin–paclitaxel was not 
found to improve PFS compared with standard carboplatin and 
paclitaxel. Median PFS for patients who received the experi-
mental therapy was 14.6 months vs 16.2 months for those who 
received the standard therapy (P = .25). This outcome parallels 
that found in Gynecologic Oncology Group (GOG) trial 182, 
which also evaluated topotecan in sequential doublets as one of 
four experimental regimens tested (19). Unlike our trial, the 
GOG study used topotecan in combination with carboplatin, 
rather than cisplatin. Furthermore, in the GOG study, 3 days of 
topotecan were given at 1.25 mg/m2 per day rather than 0.75 mg/m2 
for 5 days, and the drug administration followed the reverse 
sequence of our study, with the platinum compound given on day 
3 rather than on day 1. Although it was our hypothesis that the 
5-day schedule of topotecan with day 1 cisplatin administration 
would be synergistic and show a benefit (20), this did not occur. 
Because the topotecan-containing arm was associated with 
increased myelotoxicity, increased rates of neutropenic sepsis and 
embolic events, increased inconvenience, and did not bring a 
substantial benefit to QoL, carboplatin–paclitaxel remains the 
recommended standard of care.
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Table 4. Multivariable analysis of progression-free survival*
Factor N Adjusted hazard ratio† (95% CI) P
Treatment    
  Arm 1 409 1.11 (0.95 to 1.30) .20
  Arm 2 410 1.00
Groups    
  NCIC CTG 471 1.09 (0.92 to 1.28) .32
  Others 348 1.00
Age    
  ≤65 619 0.89 (0.74 to 1.06) .19
  >65 200 1.00
Pre-randomization surgery    
Debulking with no macroscopic residual disease and debulking with  
    macroscopic residual disease (<1 cm)
367 0.49 (0.40 to 0.61) <.001
Debulking with macroscopic residual disease (>1 cm) 284 0.83 (0.67 to 1.02) .07
No debulking 157 1.00
FIGO stage    
  II 70 0.40 (0.27 to 0.59) <.001
  III or IV 749 1.00
Grade    
  Well or moderate 208 0.90 (0.75 to 1.09) .28
  Poor/undifferentiated or unknown 611 1.00
Histology    
  Serous adenocarcinoma 545 0.94 (0.79 to 1.12) .48
  Others 274 1.00
ECOG performance status    
  0 263 0.82 (0.69 to 0.98) .03
  1 556 1.00
*  NCIC CTG = NCIC Clinical Trials Group; FIGO = International Federation of Gynecology and Obstetrics; ECOG = Eastern Cooperative Oncology Group. P values 
(two-sided) were calculated using a stratified log-rank test.
†  Hazard ratio relative to last category of each factor.
A 1 A 2
Month N S 95  CI N S       95  CI
12 369 90.2  (87.3 to 93.1) 378 92.9  (90.4 to 95.4)
24 298 72.9  (68.5 to 77.1) 306 76.1  (72.0 to 80.3)
36 170 54.4  (49.4 to 59.3) 173 58.6  (53.6 to 63.6)
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Figure 4. Kaplan–Meier curves for overall survival. An event is defined 
as death from any cause. In each graph, arm 1 is indicated by a solid 
line and arm 2 is indicated by a dashed line. No significant differences 
were found between the treatment arms. N = number at risk; S = sur-
vival percent, with 95% confidence interval in parentheses.
The cisplatin–topotecan doublet also seemed to be less effective 
than carboplatin–paclitaxel at least as measured by proportion of 
patients with CA125 normalization at 3 months, and yet, the early 
survival outcomes are similar. One explanation could be that the 
subsequent carboplatin–paclitaxel cycles compensated for this ap-
parent lesser efficacy. However, a comparison of CA125 data later 
in treatment did not support this explanation. A total of 126 
patients in arm 1 (the cisplatin–topotecan containing arm) and 88 
on arm 2 had upfront debulking and had continued elevation in 
CA125 at 3 months after randomization, and only 46 (36.5%) and 
35 (39.8%), respectively, had subsequent normalization. Thus, this 
crude analytic technique did not demonstrate any hint of a com-
pensatory increase.
Various other approaches to the integration of topotecan, in-
cluding administration of triplet combinations and consolidation 
therapy, have been evaluated in randomized studies (Table 5), but 
none were associated with an improved outcome compared with 
standard carboplatin–paclitaxel (19, 21–23). The most sensible 
explanation for this lack of additional benefit is that the topotecan 
does not have sufficient cytotoxic impact on cells that are truly 
resistant to platins or taxanes. Review of the response rates 
achieved with single-agent topotecan suggests that this is a plau-
sible explanation. For a drug to be truly “noncross resistant,” it 
should have meaningful activity in the refractory setting (ie, when 
the cancer grows during treatment), and not just in the “resistant” 
setting (ie, when it recurs shortly after completion of treatment), 
which includes short duration responders. Four single-agent 
studies of topotecan included a “refractory” subset, albeit diluted 
by including patients with stable disease (5–8). Only 9% (15 of 
169) of patients responded to topotecan. Thus, although the 
strategy of adding non–cross-resistant agents remains a reasonable 
approach to improving outcomes, the actual impact of topotecan 
in the resistant setting is likely too modest to have an impact. 
Future cytotoxic drugs need to be able to convincingly kill truly 
refractory cells before being added to the preexisting standard 
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drug or drugs for efficacy testing. The alternate explanation for the 
failure of the doublet or triplet approaches was that insufficient 
topotecan was delivered. This argument is refuted by the lack of 
additional effect seen in the two consolidation studies in which 
topotecan was delivered at the recommended single-agent dose 
over 5 days of 1.25 to 1.5 mg/m2 day.
Phase III studies are time consuming and expensive, both in 
terms of patients and volunteers and in terms of time and re-
sources. Early discontinuation of trials when the experimental 
treatment will not offer an improvement in outcomes thus 
becomes important, and finding an appropriate endpoint upon 
which to make such judgments has been elusive. Indeed, most 
often, PFS is the endpoint used for early stopping; yet, with me-
dian PFS of approximately 15 months in most frontline ovarian 
cancer trials, accrual often is completed before sufficient numbers 
of progression events have been seen to perform an interim 
analysis. The findings seen in this trial with regard to CA125 nor-
malization rates at 3 months, if confirmed in other randomized 
studies as being predictive of relative efficacy of treatment arms, 
suggest that this measure may provide an early opportunity to de-
termine futility of novel regimens in phase III studies. If this rela-
tionship between CA125 normalization rates and PFS outcome is 
confirmed in retrospective analyses of other trials, this measure 
would potentially be useful to prospectively evaluate not only cy-
totoxic combination regimens but also regimens that include tar-
geted agents when new regimens are developed that incorporate 
those types of agents.
Limitations of this study are few: it was adequately powered to 
detect the postulated difference in the primary endpoint, all 
patients were included in an intent-to-treat analysis, and sufficient 
progression events were achieved to assess the primary endpoint. 
However, the survival data are immature and the final overall 
results require continued follow-up. Thus, although the conclu-
sions are robust with respect to the lack of benefit of topotecan on 
PFS, the overall survival effects await later follow-up for this 
endpoint.
In summary, the use of four cycles of cisplatin–topotecan fol-
lowed by four cycles of carboplatin–paclitaxel did not provide 
improved PFS, QoL, or response rates compared with eight cycles 
of standard carboplatin–paclitaxel in women with newly diagnosed 
epithelial ovarian cancer at stage IIB and higher. Thus, carboplatin–
paclitaxel remains the standard of care for women with newly 
diagnosed disease.
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